ReviewCA: a cancer journal for clinicians
Cancer screening with multicancer detection tests: A translational science review.
Review in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06931561 (Occupational Cancer Screening in Firefighters), which is not on this map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Diagnostic Risk Prediction Models for Upper Gastrointestinal Cancers: A Systematic Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Pooled it
- Value of Machine Learning Models for Cell-Free DNA-Based Multi-Cancer Early Detection: A Systematic Review and Meta-Analysis.Technology in cancer research & treatmentPooled it
- Dietary and Urinary Iodine in Relation to Thyroid Cancer Risk: A Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Review
- Positive predictive value metrics for multicancer detection tests.Journal of medical screening · 2026Article
- Attention U-Net-Based Segmentation and Hybrid Classification for Detection of Circulating Tumor-Associated Cells.Cancers · 2026Article
- Tumor-educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation.International journal of cancer · 2026Review
- Increasing power and robustness in screening trials by testing stored specimens in the control arm.BMC medical research methodology · 2026Article
- Multi-cancer early detection tests: national estimates of awareness and perceived value in the United States.Cancer causes & control : CCC · 2026Article
- Geospatial heterogeneity of hotspots for incidence and late-stage diagnosis of breast, colorectal, and lung cancer.Cancer causes & control : CCC · 2026Article
- UK National Screening Committee position statement on evidence required for multicancer detection tests.BMJ (Clinical research ed.) · 2026Article
- Profiling the Onco-metabolic Nexus and Improving Cancer Risk Prediction Performance: A Large-scale Cohort and Genome-Wide Pleiotropic Analysis.Cancer research communications · 2026Article
- Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102).Journal of the National Cancer Institute · 2026Observational
- Measuring and defining screening benefit in a new era of cancer early detection.Journal of the National Cancer Institute · 2026Article
- Early Cancer Detection: What's Going on and What's Next.MedComm · 2026Review
- SERS-Based Immunoassay on Ag/ZnO Nanorod Substrates for Detection of CA125 Antigen.ACS measurement science au · 2026Article
- Multicancer Detection Assays: Promise and Potential Harms of a Novel Cancer Screening Tool.The Permanente journal · 2026Article
- Liquid Biopsy in Early Screening of Cancers: Emerging Technologies and New Prospects.Biomedicines · 2026Review
- Achieving control of nasopharyngeal carcinoma: the role of Epstein-Barr virus-based screening and vaccines.Nature reviews. Clinical oncology · 2026Review
- Plasma protein profiling predicts cancer in patients with non-specific symptoms.Nature communications · 2025Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to improve early cancer detection, including cancers that currently lack effective screening methods. However, these tests have unknown and unquantified benefits and harms. MCD tests differ from conventional cancer screening tests in that the organ responsible for a positive test is unknown, and a broad diagnostic workup may be necessary to confirm the location and type of underlying cancer. Among two prospective studies involving greater than 16,000 individuals, MCD tests identified those who had some cancers without currently recommended screening tests, including pancreas, ovary, liver, uterus, small intestine, oropharyngeal, bone, thyroid, and hematologic malignancies, at early stages. Reported MCD test sensitivities range from 27% to 95% but differ by organ and are lower for early stage cancers, for which treatment toxicity would be lowest and the potential for cure might be highest. False reassurance from a negative MCD result may reduce screening adherence, risking a loss in proven public health benefits from standard-of-care screening. Prospective clinical trials are needed to address uncertainties about MCD accuracy to detect different cancers in asymptomatic individuals, whether these tests can detect cancer sufficiently early for effective treatment and mortality reduction, the degree to which these tests may contribute to cancer overdiagnosis and overtreatment, whether MCD tests work equally well across all populations, and the appropriate diagnostic evaluation and follow-up for patients with a positive test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.